Last reviewed · How we verify
PCV20
PCV20, developed by M.D. Anderson Cancer Center, is a marketed small molecule with a specific mechanism of action, though its primary indication and revenue figures are not specified. The drug's key strength lies in its unique mechanism of interaction with a specific target, which differentiates it from other therapies. However, the primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PCV20 |
|---|---|
| Also known as | Prevnar 20™, APEXXNAR™, Prevnar 20, 20 valent pneumococcal vaccine, Prevnar 20 (in US), Apexxnar (in Europe) |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults (PHASE4)
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |